Corbus Pharmaceuticals Holdings (CRBP) Total Current Liabilities (2013 - 2025)

Corbus Pharmaceuticals Holdings has reported Total Current Liabilities for 13 years, with the latest figure at $20.7 million in Q4 2025.

• On a quarterly basis, Total Current Liabilities rose 75.09% year-over-year to $20.7 million in Q4 2025; TTM through Dec 2025 was $20.7 million, a 75.09% increase from a year earlier, with the FY2025 full-year figure at $20.7 million, up 75.09% from the prior year.
• Total Current Liabilities was $20.7 million for Q4 2025 at Corbus Pharmaceuticals Holdings, up from $17.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $31.9 million in Q4 2023, with the low at $11.6 million in Q1 2025.
• Average Total Current Liabilities over 5 years is $18.4 million, with a median of $17.0 million recorded in 2021.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities jumped 152.33% in 2023, then plunged 63.14% in 2024.
• Over 5 years, Total Current Liabilities stood at $17.0 million in 2021, then slipped by 25.68% to $12.6 million in 2022, then soared by 152.33% to $31.9 million in 2023, then slumped by 62.95% to $11.8 million in 2024, then surged by 75.09% to $20.7 million in 2025.
• The last three Total Current Liabilities figures came in at $20.7 million (Q4 2025), $17.1 million (Q3 2025), and $13.3 million (Q2 2025), per Business Quant data.